H. Lundbeck A/s

This study looks at the long-term safety of eptinezumab in 600 children and teens aged 6 to 17 who have chronic or episodic migraine. Participants must have completed a previous study of the same drug. The main goal is to track side effects over time, with additional measures of …

This study tests a new medicine called Lu AG13909 in 42 adults with congenital adrenal hyperplasia (CAH), a rare genetic condition that disrupts hormone production. The goal is to check the drug's safety, how the body processes it, and its effects on hormone levels. Participants …

This study tests whether a medicine called eptinezumab can prevent migraines in children and teens aged 6 to 17 who have episodic migraine. Participants receive the drug or a placebo by IV every 12 weeks. The main goal is to see if it reduces the number of migraine days per month…

This study tests whether eptinezumab, given by IV, can reduce the number of migraine days in teenagers aged 12 to 17 who have chronic migraines (15 or more headache days per month). Participants will receive either the drug or a placebo, and researchers will track migraine days o…

This study tests a new drug called Lu AG13909 in 18 adults with Cushing's disease, a rare condition where the body makes too much cortisol. The main goals are to see if the drug can lower cortisol to normal levels and to check its safety. Participants will receive the drug throug…